Suven Life Sciences Ltd, a biopharmaceutical company, has registered an over 100 per cent rise in net profit at Rs 8.3 crore (Rs 3.5 crore) for the fourth quarter ended March 31, 2012.
The revenue for the quarter stood at Rs 62.4 crore (Rs 46.5 crore), a growth of 34.30 per cent over the comparative quarters.
The EBIDTA also rose substantially at Rs 13.23 crore (Rs 5.66 crore), as per the unaudited financial results announced today.
Suven’s thrust on innovative R&D in drug discovery continues with a spending of Rs 8.45 crore, which is roughly 13.54 per cent of revenue for the quarter.
During the quarter, the company got three product patents. Its drug discovery pipeline has 13 molecules in various stages of development. The focus disease areas are Alzheimer’s and Schizophrenia.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.